Get the Daily Brief
Latest Biotech News
Ginkgo wins $47M DOE contract — to automate phenotyping at PNNL
Ginkgo Bioworks secured a four‑year, $47 million contract to design and integrate an automated phenotyping platform for the Pacific Northwest National Laboratory’s Microbial Molecular Phenotyping...
Hemophilia gene therapy market stalls: payers, pricing bite back
Commercial uptake for early hemophilia gene therapies has fallen short of blockbuster expectations. Market leaders have faced reimbursement resistance and pricing pushback: Biomarin explored...
CDC panel scraps universal hepatitis B birth dose: parents must consult
The Advisory Committee on Immunization Practices voted to remove the longstanding universal recommendation that newborns receive the first hepatitis B vaccine dose at birth, adopting a new...
FDA shakes up CDER: Høeg named acting director amid vaccine debate
Tracy Beth Høeg was appointed acting director of the FDA’s Center for Drug Evaluation and Research as the agency cycles through leadership after multiple changes in 2025. Her appointment has drawn...
Freenome to go public via $330M SPAC: readies for 2026 test launch
Liquid biopsy developer Freenome agreed to merge with a SPAC in a transaction expected to deliver about $330 million in proceeds, including roughly $240 million in a PIPE from healthcare...
Casgevy pediatric data previewed at ASH: gene therapy push into younger kids
Presentations at the American Society of Hematology previewed data and strategies to expand exa‑cel (Casgevy) and other gene-editing therapies into children aged 5–11 with transfusion-dependent...
Praxis stops pivotal seizure trial early — data spur stock rally
Praxis Precision Medicines halted its registrational EMBOLD Phase 2/3 study of relutrigine in developmental and epileptic encephalopathies after an interim analysis showed efficacy, prompting a...
Natera buys Foresight to widen MRD toolkit — MRD gains regulatory traction
Natera agreed to acquire Foresight Diagnostics for $275 million up front plus up to $175 million in milestone payments to bring PhasED‑Seq phased‑variant MRD technology into its Signatera...
Ginkgo wins $47M DOE contract to automate phenotyping at PNNL
Ginkgo Bioworks secured a four‑year, $47 million contract to design and integrate an automated phenotyping platform at the Pacific Northwest National Laboratory's Environmental Molecular Sciences...
Bristol Myers expands Breyanzi to marginal zone lymphoma — first CAR‑T for MZL
Bristol Myers Squibb’s CAR‑T therapy Breyanzi received FDA approval for third‑line treatment of marginal zone lymphoma, making it the first CAR‑T approved for this rare, indolent non‑Hodgkin...
Biopharma funding normalizes — $1B+ takeouts are rising
Industry financing activity through November 2025 shows normalization after post‑pandemic volatility, with November collecting $9.94 billion across 96 deals versus $13.23 billion in October. At...
Nanites and degraders: two seed rounds back diagnostics and targeted degradation
Newcastle startup Invenirex raised £2 million in seed funding to commercialize 'nanites' — programmable DNA microstructures that enable enzyme‑free nucleic acid detection with high sensitivity in...
ACIP scraps universal birth-dose — CDC set to revise hepatitis B guidance
An influential CDC vaccine advisory panel voted to remove the decades-old universal recommendation that all newborns receive the hepatitis B vaccine immediately after birth. The Advisory Committee...
Freenome to go public via $330M SPAC — cancer‑screening launch set for 2026
Freenome agreed to merge with a SPAC and raise roughly $330 million, including a $240 million PIPE, to accelerate commercialization of blood-based cancer screening tests expected in 2026. The...
Natera buys Foresight — phased‑variant MRD tech added to Signatera
Natera agreed to acquire Foresight Diagnostics for $275 million up front, plus up to $175 million in contingent payments, to integrate Foresight’s PhaseED‑Seq phased‑variant minimal residual...
MRD shows promise as surrogate endpoint in AML — pooled ASH dataset reported
Researchers presented pooled prospective data at ASH showing that minimal residual disease (MRD) negativity associates with longer overall survival in acute myeloid leukemia (AML), supporting the...
Vertex’s exa‑cel shows pediatric promise — push to expand sickle cell label
Vertex and collaborators presented pediatric data and program updates showing exa‑cel (Casgevy) producing clinically meaningful outcomes in children with sickle cell disease (SCD) and...
Praxis halts pivotal DEE trial early — relutrigine shows strong efficacy
Praxis Precision Medicines stopped its Phase 2/3 EMBOLD trial early after an interim analysis showed sufficient efficacy for relutrigine in developmental and epileptic encephalopathies (DEEs). The...
Bristol Myers wins broader Breyanzi use — first CAR‑T for marginal zone lymphoma
The FDA approved Bristol Myers Squibb’s CAR‑T therapy Breyanzi for third‑line treatment of marginal zone lymphoma, making it the first CAR‑T cleared for that rare, indolent non‑Hodgkin lymphoma...
Ginkgo wins $47M DOE contract — building automated phenotyping for PNNL
Ginkgo Bioworks secured a four‑year, $47 million contract to design and integrate an automated phenotyping platform for the Pacific Northwest National Laboratory (PNNL). The scope covers automated...